Estimated Budget Impact of Adopting the Affordable Care Act’s Required Smoking Cessation Coverage on United States Healthcare Payers by Christine L. Baker et al.
ORIGINAL RESEARCH
Estimated Budget Impact of Adopting the Affordable
Care Act’s Required Smoking Cessation Coverage
on United States Healthcare Payers
Christine L. Baker . Cheryl P. Ferrufino . Marianna Bruno .
Stacey Kowal
Received: September 28, 2016 / Published online: November 25, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Despite abundant information
on the negative impacts of smoking, more
than 40 million adult Americans continue to
smoke. The Affordable Care Act (ACA) requires
tobacco cessation as a preventive service with
no patient cost share for all FDA-approved
cessation medications. Health plans have a
vital role in supporting smoking cessation by
managing medication access, but uncertainty
remains on the gaps between smoking cessation
requirements and what is actually occurring in
practice. This study presents current cessation
patterns, real-world drug costs and plan benefit
design data, and estimates the 1- to 5-year
pharmacy budget impact of providing
ACA-required coverage for smoking cessation
products to understand the fiscal impact to a US
healthcare plan.
Methods: A closed cohort budget impact model
was developed in Microsoft Excel to estimate
current and projected costs for US payers
(commercial, Medicare, Medicaid) covering
smoking cessation medicines, with
assumptions for coverage and smoking
cessation product utilization based on current,
real-world national and state-level trends for
hypothetical commercial, Medicare, and
Medicaid plans with 1 million covered lives.
A Markov methodology with five health states
captures quit attempt and relapse patterns.
Results include the number of smokers
attempting to quit, number of successful
quitters, annual costs, and cost per-member
per-month (PMPM).
Results: The projected PMPM cost of providing
coverage for smoking cessation medications is
$0.10 for commercial, $0.06 for Medicare, and
$0.07 for Medicaid plans, reflecting a low
incremental PMPM impact of covering two
attempts ranging from $0.01 for Medicaid to
$0.02 for commercial and Medicare payers.
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Conclusion: The projected PMPM impact of
covering two quit attempts with access to all
seven cessation medications at no patient cost
share remains low. Results of this study
reinforce that the impact of adopting the ACA
requirements for smoking cessation coverage
will have a limited near-term impact on health
plan’s budgets.
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INTRODUCTION
Cigarette smoking is a serious public health
concern and, despite ongoing educational
efforts, it remains the leading
preventable cause of death in the USA [1].
Recent data from the Centers for Disease
Control and Prevention and national cohort
studies indicate that smoking is causally, or
suspected causally, related to approximately
500,000 deaths each year [1–3]. Smoking is
responsible for approximately 87% of all lung
cancer deaths, 80–90% of chronic obstructive
lung disease, and 32% of heart disease deaths
[1]. In addition to the significant mortality
burden, cigarette smoking exacts a striking
financial burden, accounting for an estimated
$133 to $176 billion in direct medical care
costs, $151 billion in lost productivity from
premature death, and almost $6 billion due to
lost productivity from secondhand smoke
exposure in the USA alone [1]. Despite this
abundance of information on the negative
health and economic impacts of smoking,
more than 40 million adult Americans
(15.1% of adults) continue to smoke
cigarettes [4].
Though the negative effects of smoking are
considerable, smoking cessation has immediate
and lasting impacts on smoker health outcomes
as well as the trajectory of healthcare spend.
Smokers see benefits in improved circulation
and lung function within 2 weeks to 3 months
of cessation [5]. Also, within 1 year of cessation,
smoking-related excess risk of coronary heart
disease reduces to half that of a current smoker,
and by 5 years, throat, mouth, esophageal, and
bladder cancer risks are halved [5]. After
20 years, excess risks for pancreatic cancer,
cardiovascular-related mortality, and female
mortality are reduced to that of a never
smoker [6–8]. The impact of cessation on
morbidity and mortality can also have a large
effect on healthcare spending. A recent study
focusing on smoking and expenditures in the
US concluded that a 10% relative drop in
smoking in each state would result in an
estimated $63 billion reduction (in 2012 US
dollars) in healthcare costs the following year
[9].
Increasing access to smoking cessation tools
and resources is integral in promoting smoking
cessation, increasing quit rates, and reducing the
burdenof smoking.Anestimated70%of smokers
want to quit smoking, 42.7% try to quit each
year, and 30.8% use smoking cessation
treatments [1, 10]. Unaided, the success rate is
approximately 5% [10, 11]. Smoking cessation
treatment, including behavioral interventions
and US Food and Drug Administration
(FDA)-approved pharmacotherapy for cessation,
has been rated as one of the most effective
preventive health services by the US Preventive
Services Task Force [12]. Recognizing the
evidence base on the value of pharmacotherapy
options, the US Department of Health and
Human Services clinical practice guidelines
recommend that all smokers trying to quit be
given pharmacotherapy for cessation, except
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when medically contraindicated or in special
populations with insufficient evidence of
effectiveness (i.e., pregnant women,
adolescents) [13]. Therefore, it is not
unexpected that tobacco cessation services were
incorporated as a principle of the Patient
Protection and Affordable Care Act (ACA; Pub L
No. 111—148) [14].
Under the ACA, tobacco cessation is
included as a required preventive service with
no patient cost share. Specifically, according to
guidance issued in May 2014 by the
Departments of Health and Human Services,
Labor and Treasury, a health plan will be
considered to be in compliance if they cover
(1) screening for tobacco use, (2) at least two
quit attempts per year that include four sessions
of counseling and 90 days of medication per
quit attempt, (3) individual or group counseling
(at least 10 min per session), and (4) all
FDA-approved tobacco cessation medications
(prescription and over the counter) when
prescribed by a healthcare provider without
prior authorization or patient cost share [15].
Health plans manage health benefits and
medication access through their prescription
formularies and product coverage and,
therefore, play a vital role in supporting
smoking cessation. A March 2015 study by the
American Lung Association found that less than
20% of plan insurers were offering sufficient
coverage and fewer than 50% listed the seven
approved cessation medications on their
formularies [16]. An August 2015 an update to
that report found a dramatic increase in the
availability of formularies and other documents
highlighting coverage for smoking cessation
and guidance for subscribers on coverage
access for smoking cessation [17].
However, uncertainty remains on the gaps
between smoking cessation requirements and
what is actually occurring in practice. Further,
health plans bear the fiscal burden for
operationalizing ACA requirements. The true
fiscal impact of adopting ACA requirements is
dependent on a multitude of factors, ranging
from current patient cost sharing practices to
smoking cessation trends to the efficacy of
cessation medications. In this study, we first
gather data on current cessation patterns as well
as real-world drug costs and plan benefit design
data to articulate the current cost of providing
access to smoking cessation medicines and to
highlight the gaps between current coverage
and ACA requirements. Next, we estimate the 1-
to 5-year pharmacy budget impact of providing
ACA-required coverage for smoking cessation
products to understand the fiscal impact to a US
healthcare plan.
METHODS
Smoking Cessation Budget Impact Model
Framework
A budget impact model was developed in
Microsoft Excel to simulate current and
projected costs for health plans covering
cessation medicines. The model takes the
perspective of a US healthcare payer, using
nationally representative default scenarios
developed for public (Medicare, Medicaid) and
private (commercial) payers. The model
leverages a market-based approach to estimate
the pharmacy budget impact of providing
ACA-required coverage for smoking cessation
products. First, the model estimates the current
(or baseline) annual budget for a health plan,
with assumptions for coverage and smoking
cessation product utilization based on current,
real-worldnational and state-level trends.Next, a
projected scenario is generatedwhich adjusts the
coverage parameters to reflect optimized
ACA-required coverage. Finally, the budget
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impact of adopting the ACA-required smoking
cessation coverage is the difference between the
baseline (current world) and projected
(ACA-required) estimates. Model results include
the number of smokers attempting to quit with
covered products, number of successful quitters,
annual costs, and cost per-member per-month
(PMPM). Please note that this article does not
contain any new studies with human or animal
subjects performed by any of the authors but is
based on previously published literature.
To simulate patterns for quit attempts,
smoking relapse, and cessation success, the
model utilizes a Markov methodology with
five health states and 6-month cycle lengths
(Fig. 1). To estimate the number of successful
quitters, the model begins with the entire
population of adult smokers. Among the
population that attempts to quit, a portion
will utilize pharmaceutical smoking cessation
medications and the remaining will attempt to
quit without aids.
Model Inputs
Data inputs in the model are populated with
information from peer-reviewed literature,
publicly available data sources, and the IMS
National Prescription AuditTM (NPA) [18]. The
model base-case estimates impact of offering
ACA coverage for a hypothetical health plan
with 1 million covered lives. A closed cohort
model is used, where no smokers enter over
time and smokers can only leave as a result of
all-cause mortality [19]. This approach helps to
isolate the impact of smoking cessation on a
given population of smokers over time.
Information on the age and gender
distribution of the US population from the US
census, national estimates for the prevalence of
smoking, annual quit attempts, and the
utilization of smoking cessation products are
leveraged to isolate the population of smokers
using smoking cessation products filled by a
prescription that would be covered by their
health plan [10, 20–22]. In the base case, the
model assumes the same utilization of
prescription cessation medications (7.4%),
among the population using prescription and
over the counter (OTC) medications, across age
groups and payer types [18].
The national commercial and Medicaid
population inputs can be found in Table 1.
Starting with a hypothetical plan of 1 million
Health State Descripons: 
Eligible Smoker:  Adult smokers who are eligible to quit smoking with a smoking cessaon aid during the current year.  This 
includes: 
(1) Smokers who have never aempted to quit,  
(2) Smokers who have previously aempted to quit and failed,  
(3) Successful quiers who subsequently relapsed 
Ineligible Smoker:   This tunnel state is used when modeling one covered quit aempt per year. This state holds smokers 
who are not eligible to quit smoking because they failed a quit aempt less than 12 months prior to their current quit 
aempt. When modeling two quit aempts per year, smokers return to ‘Eligible Smoker’ in the ﬁrst cycle aer their 
relapse. 
Inial Quier:  A tunnel state for smokers who have aempted to quit in the current year, and are currently absnent 
from smoking during the current cycle but who have not yet met the criteria for ‘Successful Quier’. 
Successful Quier:  Consists of inial quiers who have abstained from smoking for the required length of me to meet 
the clinical deﬁnion of success and who have not relapsed. The model assumes that a person becomes a ‘Successful 
Quier’ aer being absnent from smoking for one full year. 
Death: Captures death due to all-cause mortality, based on age- and gender-adjusted rates from US life tables from the 
Centers for Disease Control and Prevenon [19].
Fig. 1 Markov framework
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covered lives, the model estimates 128,987 adult
smokers, 67,004 smokers attempting to quit
annually, and 1527 people utilizing smoking
cessation medications that were filled via a
prescription for commercial and Medicaid
plans. The model focuses solely on the use of
smoking cessation medications filled via
prescription, as these medications would
Table 1 National commercial and Medicaid population inputs
Inputs to estimate adult smokers (plan of 1 million covered lives)
Population distribution [20] Male population Female population Plan population
% No. males % No. females Males and females
0–12 8.33 83,339 7.98 79,762 163,101
13–17 8.29 32,892 3.15 31,487 64,379
18–24 4.90 49,028 4.65 46,491 95,519
25–44 13.28 132,753 13.10 130,960 263,713
45–64 12.73 127,289 13.35 133,465 260,754
65? 6.76 67,578 8.50 84,956 152,534
Total adult (18?) 376,648 395,872 772,520






0–12 0.00 0.00 0
13–17 18.50 6085 14.80 4660 10,745
18–24 18.50 9070 14.80 6881 15,951
25–44 22.90 30,400 17.20 22,525 52,926
45–64 19.40 24,694 16.80 22,422 47,116
65? 9.80 6623 7.50 6372 12,994
Total adult (18?) 70,787 58,200 128,987







% Total quitters % Aids % Quitters
13–24 61.90 9874 12.70 1254 7.40 93
25–44 53.30 28,209 28.30 7983 7.40 591
45–64 49.00 23,037 40.40 9327 7.40 690
65? 44.90 5834 35.50 2071 7.40 153
Total adult (13?) 67,004 20,636 1527
Inputs for estimating eligible quitters represent both male and female populations combined; Information on the number of
individuals in the 13–17 age group is collected to allow for patients to age into the model over the 5-year time horizon
The model maintains maximum precision in the population calculations. Therefore, numbers may not sum due to rounding
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impact health plan budgets. Any products
obtained without a prescription, including
some OTC medications, are not considered in
the current analysis.Note that although smoking
cessation medications are indicated for an adult
population (18?), the population ages 13–17 are
estimated to account for individuals who will
become 18 years of age and enter themodel over
the 5-year time horizon. When estimating the
eligible population for Medicare plans, we
restricted the population to individuals aged
65, resulting in 85,083 adult smokers, 38,202
total smokers attempting to quit annually, and
1004 individuals utilizing smoking cessation aids
filled by a prescription.
The model includes the seven FDA-approved
forms of smoking cessation products, including
five forms of nicotine replacement therapy (NRT)
(patch, gum, lozenge,nasal spray, and inhalers) as
well as two non-NRT medications (bupropion SR
and varenicline) [13]. Note that OTC NRTs are
included to account for NRT therapies being
dispensed by prescription and covered under the
ACA, as captured in the IMS NPA data [18].
Therefore, while the model only examines
smokers utilizing prescription smoking cessation
therapies, some OTC medicines are included if
they were dispensed with a prescription.
Data on utilization and pricing of smoking
cessation medications as well as patient cost
share trends are based on IMS NPA data as of
January 2016 [18]. Table 2 lists the national
commercial inputs for product utilization and
cost. Detailed information on market share and
drug cost inputs for Medicare and Medicaid
scenarios are provided in the Supplementary
Appendix. The NPA database contains
pharmacy records from over 37,000 retail
pharmacies, including independent
pharmacies, chain pharmacies, pharmacies in
discount outlets, and pharmacies in food stores.
Additionally, it includes feeds from mail service
houses, pharmacy benefit managers, and
long-term care facilities. The national sample
includes sources located in all 50 states. It
captures approximately 74% of all
prescriptions and projects the remaining 26%.
Given that this analysis estimates the cost
related to changes in smoking cessation
coverage under the ACA, utilization patterns
among smoking cessation products (i.e., market
shares) are assumed constant over the 5-year
model time horizon in the base-case analysis.
Late relapse is used to estimate the number
of former smokers who were successful quitters
(e.g., have quit for 12 months) but then
eventually relapse to account for a return to
smoking after a period of initial success.
Published data supports the assumption that
as the duration of time since quitting increases,
relapse decreases. Therefore, an annual relapse
rate of 6.3% based on previously published
studies was utilized in the model [23, 24].
Smoking cessation intervention efficacy is
based on data drawn from a Cochrane
systematic review [25]. Systematic reviews were
used rather than head-to-head trials to
maximize the number of treatments included
in the model and to characterize a wide-ranging
analysis of available efficacy data. The
12-month quit rate for placebo (9.3%) was
based on a pooled analysis of 52-week
continuous abstinence rates from two
randomized controlled trials comparing
varenicline, bupropion, and placebo [26].
Efficacy information for unaided cessation
(5.0%) was also collected to model cessation
patterns for individuals trying to quit smoking
without using any cessation medications [11].
All smokers are eligible for quit attempts. The
model also includes smokers who attempt to
quit without smoking cessation
pharmacotherapy to account for smokers who
may successfully quit unaided and to accurately
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Table 2 National commercial inputs for product utilization and unit costs [18]
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model the relapse patterns and additional
cessation attempts (with and without smoking
cessation medications) for the entire group over
the model time horizon. Results from the model
represent outcomes only for smokers who
attempt to quit using smoking cessation
medications filled by prescription to estimate
the pharmacy budget impact of smoking
cessation coverage to a health plan. Table 3
highlights the efficacy rates of smoking
cessation interventions.
Model Base Case
The inputs and assumptions used in the
base-case scenario were chosen to compare the
current smoking cessation intervention usage
and average patient out of pocket costs and
medication unit costs to a projected scenario
where health plans follow ACA-required
guidance for smoking cessation coverage. The
Table 3 Efﬁcacy rates of smoking cessation interventions
[25, 26]





NRT GUM 1.68 14.7
NRT INHALER 1.84 15.9
NRT LOZENGE 1.84 15.9
NRT NASAL SPRAY 1.84 15.9
NRT PATCH 1.91 16.4
Table 2 continued
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model uses national rates, and by default, the
current scenario assumes one quit attempt per
year. The projected scenario utilizes inputs and
assumptions to reflect optimal ACA coverage,
including the removal of all patient cost sharing
and ensuring that each quitter is eligible for two
covered quit attempts per year.
RESULTS
For hypothetical nationally representative plans
the current total 1- to 5-year average PMPM cost
of providing coverage for smoking cessation
medications is $0.08 for commercial, $0.05 for
Medicare, and $0.05 for Medicaid plans. For the
projected scenario based on ACA optimization,
the PMPM cost is $0.10 for commercial, $0.06
for Medicare, and $0.07 for Medicaid plans. The
resulting incremental PMPM budget impact is
low, ranging from $0.01 for Medicare to $0.02
for commercial and Medicaid payers. The
budget impact reflects two covered attempts to
quit smoking with no cost share for smoker
access to all seven cessation medications. The
results reflect a conservative analysis that
considers pharmacy costs only, without
considering the additional direct medical cost
offsets associated with smoking cessation.
Across all 5 years and the scenarios
considered, the relative increase in number of
successful quitters exceeds the relative increase
in the number of smokers attempting to quit.
Over 5 years, there is a 20.4% increase in the
number of smokers attempting to quit, and a
22.2% increase in the number of successful
quitters in the commercial plan. Similar trends
in smokers attempting to quit and successful
quitters are also observed for Medicare (17.6%
and 19.2%, respectively) and Medicaid (20.4%
and 22.3%, respectively) plans. This reflects
smokers’ second opportunity to quit smoking
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increases the overall likelihood of quitting. The
declining estimates for the total numbers of
smokers attempting to quit reflect the closed
cohort nature of the model. Within the closed
cohort, no new smokers enter but some leave as
a result of all-cause mortality. Therefore, the
number of smokers, and therefore eligible
quitters, is slightly reduced each year. Please
see Table 4 for details.
A change in benefit to cover two quit
attempts per year increases the number of
smokers attempting to quit by approximately
20% across scenarios and settings. By adopting
ACA-required coverage and assuming
utilization is held constant, a commercial plan
would support a total of 1480 additional
quitters over 5 years (an average of 280 per
year), while Medicaid and Medicare plans
would support 742 (average of 148/year) and
1406 (average of 281/year), respectively.
Primary drivers of differences across scenarios
include the eligible population (Medicare is 65
and over), patient cost share, and drug prices
and market shares for cessation medications.
National commercial plans have a high
utilization of varenicline ([68%), which
translates to higher success rates for quitters
overall given the higher efficacy rate of
varenicline relative to other medications [25].
National Medicare plans also have a high
utilization of varenicline ([77%), supporting
high quit rates. However, patient cost sharing
estimates are notably higher in the Medicare
payer population vs. other payers for many
products, resulting in a larger relative plan
impact PMPM when patient cost sharing is
removed. However, the absolute cost for both
Medicare and Medicaid coverage is lower
compared to commercial plans because the
National Medicaid plans use the largest
number of patches (over 56%), which have a
lower efficacy rate than varenicline according to
Cochrane meta-analysis, resulting in a lower
number of successful quits per eligible quitter
[25]. However, patient cost sharing estimates are
low for Medicaid plans, mitigating the impact of
removing patient co-pays on plan PMPM
impact.
DISCUSSION
Across all three payer scenarios, the PMPM
impact is low and the results of our analysis
indicate that the economic impact of ACA
smoking cessation requirements in health
plans is fiscally reasonable. Further, given that
the model does not consider the medical cost
offsets gained from smoking cessation and
evaluates only medication costs, the estimated
impact is likely lower than overall gains in cost
savings realized by payers when covering
smoking cessation treatments. Across all
scenarios investigated, increased access to
smoking cessation medications and coverage
of two quit attempts translated into increases in
successful quitters, with relative gains in
quitters exceeding relative increases in health
plan spend. While information on
improvements in outcomes and quality of life
resonate with smokers, providers, and
healthcare payers alike, healthcare payers must
consider the fiscal burden of the initial
investment in smoking decisions when
operating within limited budgets. Findings of
this study reinforce that the impact of adopting
the ACA requirements for smoking cessation
coverage may have a limited near-term impact
on a health plan’s budget. Considering the
individual and public health benefits of
reducing smoking, implementing ACA
recommendations seems fiscally reasonable.
To our knowledge, no other studies have
examined the impact of adopting the
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ACA-required smoking cessation coverage on
healthcare plan budgets. Previously published
budget impact models for smoking cessation
programs have estimated per member per
month impact between $0.10 and $0.40 on
healthcare plans [27]. However, these earlier
studies are not directly analogous given
differences in the targeted smoking cessation
interventions, the cost and utilization patterns
for smoking cessation interventions at the time
of the study, and the lack of explicit
consideration of ACA requirements.
As with any research based on real-world
data and economic modeling, this study is
subject to several limitations that should be
considered when interpreting results.
Information on utilization and costs for
smoking cessation interventions is based on
NPA data. While this data set offers a nationally
representative view of real-world trends, it only
covers about 74% of all prescriptions and
estimates remaining trends via projections.
This analysis does not consider changes in
utilization which are likely to occur with the
increased benefit under ACA. Direct
head-to-head randomized data was not
available for all smoking cessation
interventions in the model, necessitating the
use of information from systematic review and
meta-analyses for indirect comparison. The
most recent Cochrane review that included all
relevant FDA-approved smoking cessation
medications was chosen to ensure that a
single, robust source leveraged for all
comparator efficacy estimates. A series of
univariate and multivariate analyses were
performed to test the impact of uncertainty on
point estimates for smoking cessation
medication efficacy on model outcomes. The
lower and upper bounds of the 95% confidence
interval for each product were tested in
univariate analysis and two multivariate
analyses explored the impact of using the
lower confidence internal or upper confidence
interval for all products simultaneously [25].
While each scenario resulted in slight changes
to model results, the net impact on incremental
PMPM estimates was $0.01 PMPM or less across
all scenarios. This suggests that the conclusions
presented herein remain robust across changes
in efficacy point estimates for included
products. Further, the model assumes that the
impact of non-prescription cessation tools,
including counseling, is non-differential across
smoking cessation products and does not
impact the model estimates. And, finally, the
model does not explicitly account for the
potential impact of utilization changes,
smoker adherence or persistence on the
estimated number of successful quitters or the
cost of smoking cessation interventions.
Utilization changes are likely to occur with the
increased benefit under ACA because more
patients may utilize smoking cessation therapy
when the cost barrier is alleviated.
Even while taking into account these
limitations, there are several important
implications of this research worth noting.
Specific aspects of the ACA requirements are
essential to ensuring success with cessation.
First, the elimination of cost sharing is
foundational to providing access to effective
medications and supporting potentially higher
quit rates. This was observed in a Cochrane
review comparing abstinence rates for
individuals with and without full coverage
programs. Specifically, the relative risk for
abstinence at 6 months or more with full
financial coverage compared to no coverage
was 2.45 (95% confidence interval [CI]
1.17–5.12) [28]. There was also a positive effect
of full financial interventions on the number of
participants making a quit attempt (RR 1.11,
95% CI 1.04–1.32) and use of smoking cessation
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treatment [28]. Further, access to the full range
of pharmacotherapy options can also achieve
the goal of long-term abstinence [29]. The US
Department of Health and Human Services
clinical practice guidelines, as well as
recommendations of the ACA, reinforce the
importance of providing access to a full range of
proven smoking cessation medications [13, 14].
From a PMPM perspective, the net impact to
a plan increases marginally over all scenarios
from $0.01 (Medicaid) to $0.02 (commercial)
when the ACA guidelines are optimized.
However, these estimates still fall below the
$0.10 to $0.40 PMPM range seen in previous
budget impact models for smoking cessation
medications [27]. Given the proven efficacy of
pharmacotherapy for smoking cessation,
near-term investment in supporting the
ACA-required smoking cessation benefits may
translate into a long-term return on investment
in health and economic outcomes [30].
Changes in healthcare spending are realized
quickly after changes in smoking behavior
[31–33]. Once patients stop smoking,
immediate health benefits are realized and
healthcare and societal costs decline [9].
Therefore, health plan policies and benefits
that determine and support smoking cessation
are essential to help reduce healthcare costs.
CONCLUSION
This study provides real-world evidence-based
information on utilization patterns for
prescription smoking cessation products,
national average cost, and patient cost
sharing. This study also provides direct
estimates of the financial impact of adopting
ACA-required smoking cessation coverage to a
US health plan. This adds a tangible and
actionable perspective for plan sponsors and
individuals responsible for making budgetary
decisions and ultimately supporting efforts to
address an ongoing public health dilemma.
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